Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F1L22
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,472
Award facts
- Contract value 100% obligated
- $18,471.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,471.65 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit dose packaging) on December 1, 2025, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare procurement through the DLA Medical Supply Chain. The company's comprehensive pharmaceutical portfolio under its prime IDC includes brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for RINVOQ ER, a rheumatoid arthritis treatment, exemplifies AmerisourceBergen's role in supplying specialty medications to support Defense Health Agency and other government healthcare systems. The DLA plans to establish multiple Pharmaceutical Prime Vendor Global Program Generation V contracts across separate regions, positioning AmerisourceBergen among the anticipated major vendors for this strategic medical supply initiative.
Quick answers
Who was awarded contract SPE2DR26F1L22?
SPE2DR26F1L22 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26F1L22 worth?
The government has obligated $18,472 on SPE2DR26F1L22.
Is contract SPE2DR26F1L22 an order under another contract?
Yes. SPE2DR26F1L22 is a delivery order under SPE2DR25D2205, an indefinite delivery contract.
Was contract SPE2DR26F1L22 competed?
The extent of competition for SPE2DR26F1L22 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award